Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial

Executive Summary

Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)

You may also be interested in...



Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response

Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006

Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response

Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006

Firms Tighten Tysabri Indication To Gain Panel Endorsement For Crohn’s

Given safety issues linked to Biogen Idec/Elan's Tysabri (natalizumab), the companies are narrowing the scope of the requested Crohn's disease indication from that initially proposed and studied in the clinical trials

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel